A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection: A large-scale, multicenter study

医学 列线图 肝细胞癌 乙型肝炎表面抗原 肝切除术 回顾性队列研究 队列 内科学 比例危险模型 肿瘤科 放射科 外科 切除术 乙型肝炎病毒 病毒学 病毒
作者
Xiuping Zhang,Zhenhua Chen,Tengfei Zhou,Le‐Qun Li,Minshan Chen,Tianfu Wen,Jie Shi,Wei‐Xing Guo,Mengchao Wu,Wan Yee Lau,Shuqun Cheng
出处
期刊:Ejso [Elsevier BV]
卷期号:45 (9): 1644-1651 被引量:37
标识
DOI:10.1016/j.ejso.2019.03.043
摘要

Background Portal vein tumour thrombus (PVTT) is a significant poor prognostic factor for hepatocellular carcinoma (HCC). Patients with PVTT limited to a first-order branch or above of the main portal vein (MPV) could benefit from R0 liver resection (LR). A nomogram is needed to predict early postoperative recurrence (ER) in HCC patients with PVTT and to guide selection of these patients for adjuvant therapy to reduce postoperative recurrence risks. Methods HCC patients with PVTT limited to a first-order branch or above of the MPV after R0 LR as an initial therapy were included. A nomogram using data from a retrospective training cohort was developed with the Cox regression model. The model was tested in a prospective internal validation cohort and three external validation cohorts. Results Of 979 patients, 657 developed postoperative ER (67.1%). ER occurred in 165 of 264 patients (62.5%) in the training cohort, 146 of 218 patients (70.0%) in the internal validation cohort, and 204 of 284 patients (71.8%), 77 of 113 patients (68.1%), and 65 of 100 patients (65%) in the three external validation cohorts, respectively. The nomogram included the following variables: hepatitis B surface antigen (HBsAg), PVTT, HBV DNA, satellite nodules, α-fetoprotein, and tumour diameter. The ROC were 0.836, 0.763, 0.802, 0.837, and 0.846 in predicting ER in the five respective cohorts. Conclusion A nomogram was developed and validated to predict postoperative ER in patients with HCC with PVTT after R0 LR. This nomogram could select appropriate patients with high ER risks for postoperative adjuvant therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
满意的柏柳完成签到,获得积分10
刚刚
1秒前
NexusExplorer应助科研通管家采纳,获得30
1秒前
ED应助科研通管家采纳,获得10
1秒前
SciGPT应助科研通管家采纳,获得10
1秒前
打打应助科研通管家采纳,获得30
1秒前
foam应助科研通管家采纳,获得10
1秒前
脑洞疼应助科研通管家采纳,获得10
1秒前
无花果应助科研通管家采纳,获得20
1秒前
1秒前
完美世界应助科研通管家采纳,获得10
1秒前
桐桐应助科研通管家采纳,获得10
1秒前
今后应助科研通管家采纳,获得10
1秒前
Hello应助科研通管家采纳,获得10
2秒前
Jasper应助科研通管家采纳,获得10
2秒前
2秒前
2秒前
雨夜星空应助科研通管家采纳,获得10
2秒前
Pothos应助科研通管家采纳,获得10
2秒前
爆米花应助科研通管家采纳,获得10
2秒前
5秒前
希望天下0贩的0应助laochen采纳,获得10
11秒前
11秒前
英姑应助fnunu采纳,获得10
15秒前
20秒前
22秒前
冰魂应助奉宣室以何年采纳,获得10
23秒前
yangjinru完成签到 ,获得积分10
23秒前
25秒前
席田兰发布了新的文献求助10
26秒前
26秒前
解师完成签到,获得积分20
27秒前
laochen发布了新的文献求助10
27秒前
健壮问兰完成签到 ,获得积分10
28秒前
28秒前
stitch发布了新的文献求助10
29秒前
笑嘻嘻完成签到,获得积分10
30秒前
31秒前
研友_CCQ_M完成签到,获得积分10
32秒前
比大家发布了新的文献求助10
34秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
Maneuvering of a Damaged Navy Combatant 650
Mindfulness and Character Strengths: A Practitioner's Guide to MBSP 380
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3776524
求助须知:如何正确求助?哪些是违规求助? 3322078
关于积分的说明 10208657
捐赠科研通 3037336
什么是DOI,文献DOI怎么找? 1666647
邀请新用户注册赠送积分活动 797596
科研通“疑难数据库(出版商)”最低求助积分说明 757878